These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 33014302)

  • 1. PCSK9 Monoclonal Antibodies: An Overview.
    Kaddoura R; Orabi B; Salam AM
    Heart Views; 2020; 21(2):97-103. PubMed ID: 33014302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
    Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events.
    Turgeon RD; Pearson GJ
    Am J Health Syst Pharm; 2018 Jun; 75(11):747-754. PubMed ID: 29802110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update.
    Kaddoura R; Orabi B; Salam AM
    J Drug Assess; 2020 Aug; 9(1):129-144. PubMed ID: 32939318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
    J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
    Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
    Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia.
    Parikh RR; Breve F; Magnusson P; Behzadi P; Pergolizzi J
    Cureus; 2022 Jun; 14(6):e25641. PubMed ID: 35795514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.
    White CM
    Ann Pharmacother; 2015 Dec; 49(12):1327-35. PubMed ID: 26424774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
    Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of PCSK9 monoclonal antibodies.
    Iqbal Z; Dhage S; Mohamad JB; Abdel-Razik A; Donn R; Malik R; Ho JH; Liu Y; Adam S; Isa B; Stefanutti C; Soran H
    Expert Opin Drug Saf; 2019 Dec; 18(12):1191-1201. PubMed ID: 31623472
    [No Abstract]   [Full Text] [Related]  

  • 16. PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia.
    Verbeek R; Stoekenbroek RM; Hovingh GK
    Eur J Pharmacol; 2015 Sep; 763(Pt A):38-47. PubMed ID: 25989132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of monoclonal antibodies against PCSK9 on clinical cardiovascular events : A meta-analysis of randomized controlled trials.
    Zhu Y; Shen X; Jiang Q; Wang Z; Wang Z; Dong X; Li J; Han Q; Zhao J; Wang B; Liu L
    Herz; 2019 Jun; 44(4):336-346. PubMed ID: 29116337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia.
    White CM
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):301-308. PubMed ID: 29649884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia.
    Schmitz J; Gouni-Berthold I
    Curr Pharm Des; 2017; 23(10):1484-1494. PubMed ID: 28137217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.